Effect of cetuximab plus FOLFOX4 regimen on clinical outcomes in advanced gastric carcinoma patients receiving evidence-based care

Table 1 Baseline information

Classification	Research group (n = 60)	Control group (n = 57)	χ2/t	P value
Age (yr)	58.53 ± 7.49	56.84 ± 5.55	1.381	0.170
Sex (male/female)	40/20	34/23	0.619	0.431
Disease course (yr)	2.43 ± 1.01	2.23 ± 0.82	1.172	0.244
Pathological stage (IIIa/IIIb)	35/25	40/17	1.781	0.182
Differentiation degree (low/moderate or high)	21/39	22/35	0.163	0.687
Tumor diameter (cm)	3.71 ± 0.69	3.47 ± 0.79	1.753	0.082